Abstract
Protein therapeutics offer distinct advantages over other classes of drugs largely due to the high level of target specificity and generally low toxicity. Problems have, however, been encountered with some protein therapeutics inducing undesirable immune responses in patients. This immunogenicity can produce pleiotropic effects including the development of a high affinity B cell-mediated humoral response that is often directed against the therapeutic. Opinions are divided as to the principal causes of clinical immunogenicity and, as a result, this area has been the subject of much research. One thing that has emerged as a result of this intense activity is the development of pre-clinical models that can provide a level of prediction of the immunogenic potential of novel protein therapeutics before administration in man.
Keywords: Immunogenicity, deimmunization, T cell epitopes, protein therapeutics
Current Drug Safety
Title: Pre-Clinical Considerations in the Assessment of Immunogenicity for Protein Therapeutics
Volume: 5 Issue: 4
Author(s): Matthew P. Baker and Francis J. Carr
Affiliation:
Keywords: Immunogenicity, deimmunization, T cell epitopes, protein therapeutics
Abstract: Protein therapeutics offer distinct advantages over other classes of drugs largely due to the high level of target specificity and generally low toxicity. Problems have, however, been encountered with some protein therapeutics inducing undesirable immune responses in patients. This immunogenicity can produce pleiotropic effects including the development of a high affinity B cell-mediated humoral response that is often directed against the therapeutic. Opinions are divided as to the principal causes of clinical immunogenicity and, as a result, this area has been the subject of much research. One thing that has emerged as a result of this intense activity is the development of pre-clinical models that can provide a level of prediction of the immunogenic potential of novel protein therapeutics before administration in man.
Export Options
About this article
Cite this article as:
Baker P. Matthew and Carr J. Francis, Pre-Clinical Considerations in the Assessment of Immunogenicity for Protein Therapeutics, Current Drug Safety 2010; 5 (4) . https://dx.doi.org/10.2174/157488610792246000
DOI https://dx.doi.org/10.2174/157488610792246000 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Microneedle Patches as Drug and Vaccine Delivery Platform
Current Medicinal Chemistry Vitamin D: A Pleiotropic Hormone with Possible Psychotropic Activities
Current Medicinal Chemistry Nanocarrier based Antiretroviral Drug Delivery Approaches
Pharmaceutical Nanotechnology Myelin Sheaths and Autoimmune Response Induced by Myelin Proteins and Alphaviruses. I. Physicochemical Background
Current Medicinal Chemistry Nanoparticle Enabled Drug Delivery Across the Blood Brain Barrier: in vivo and in vitro Models, Opportunities and Challenges
Current Pharmaceutical Biotechnology Meet Our Editorial Board Member
Clinical Cancer Drugs Toll-Like Receptors and Human Disease: Lessons from Single Nucleotide Polymorphisms
Current Genomics Postoperative Care of the Transplanted Patient
Current Cardiology Reviews Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges
Current Neuropharmacology The Role of α7 Nicotinic Acetylcholine Receptors and α7-Specific Antibodies in Neuroinflammation Related to Alzheimer Disease
Current Pharmaceutical Design Conditional Tat Protein Brain Expression in the GT-tg Bigenic Mouse Induces Cerebral Fractional Anisotropy Abnormalities
Current HIV Research ACE Inhibition, p300, Serum Nitrite and Lipid Peroxidation in Newly Diagnosed Hypertensives
Vascular Disease Prevention (Discontinued) Pharmacological Modulation of Th17
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot topic: Structural Disorder in Viral Proteins (Guest Editor: Sonia Longhi)]
Protein & Peptide Letters Suicide Gene Therapy Against Malignant Gliomas by the Local Delivery of Genetically Engineered Umbilical Cord Mesenchymal Stem Cells as Cellular Vehicles
Current Gene Therapy COVID-19, the Brain, and the Future: Is Infection by the Novel Coronavirus a Harbinger of Neurodegeneration?
CNS & Neurological Disorders - Drug Targets The Potential Role of Pro-Inflammatory and Anti-Inflammatory Cytokines in Epilepsy Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Specific Roles of NMDA Receptor Subunits in Mental Disorders
Current Molecular Medicine Intracellular Amyloid β-Protein and Its Associated Molecules in the Pathogenesis of Alzheimers Disease
Mini-Reviews in Medicinal Chemistry Brain Endothelial Cell-Cell Junctions: How to “Open” the Blood Brain Barrier
Current Neuropharmacology